Koss-Olinger Consulting’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.52M | Sell |
65,736
-2,460
| -4% | -$94.5K | 0.21% | 55 |
|
|
2025
Q1 | $2.64M | Buy |
68,196
+227
| +0.3% | +$8.79K | 0.22% | 50 |
|
|
2024
Q4 | $2.3M | Buy |
67,969
+5,583
| +9% | +$189K | 0.2% | 58 |
|
|
2024
Q3 | $2.55M | Sell |
62,386
-495
| -0.8% | -$20.2K | 0.22% | 56 |
|
|
2024
Q2 | $2.42M | Buy |
+62,881
| New | +$2.42M | 0.22% | 55 |
|
|
2024
Q1 | – | Sell |
-56,451
| Closed | -$2.09M | – | 142 |
|
|
2023
Q4 | $2.09M | Buy |
56,451
+3,734
| +7% | +$138K | 0.21% | 52 |
|
|
2023
Q3 | $1.91M | Buy |
52,717
+2,487
| +5% | +$90.2K | 0.28% | 45 |
|
|
2023
Q2 | $1.79M | Sell |
50,230
-820
| -2% | -$29.2K | 0.21% | 59 |
|
|
2023
Q1 | $1.82M | Buy |
51,050
+1,067
| +2% | +$38K | 0.23% | 49 |
|
|
2022
Q4 | $1.76M | Buy |
49,983
+32,935
| +193% | +$1.16M | 0.25% | 39 |
|
|
2022
Q3 | $502K | Buy |
17,048
+12,745
| +296% | +$375K | 0.09% | 100 |
|
|
2022
Q2 | $234K | Sell |
4,303
-1,536
| -26% | -$83.5K | 0.04% | 150 |
|
|
2022
Q1 | $318K | Buy |
5,839
+193
| +3% | +$10.5K | 0.05% | 145 |
|
|
2021
Q4 | $311K | Buy |
5,646
+14
| +0.2% | +$771 | 0.05% | 152 |
|
|
2021
Q3 | $269K | Buy |
+5,632
| New | +$269K | 0.04% | 187 |
|